Endothelial microparticle (EMP) (EMP)

Endothelial microparticles (EMPs) are submicron extracellular vesicles, typically ranging from 100 nm to 1 μm in diameter, that are shed from the plasma membrane of endothelial cells in response to activation, injury, or apoptosis [1, 10]. They function as sophisticated biological vectors that transport a diverse array of cargo, including cell-surface proteins (such as CD31, CD144, and E-selectin), lipids like phosphatidylserine, and various nucleic acids, facilitating complex intercellular communication [3, 10]. EMPs play a dual and often ambivalent role in vascular homeostasis; they can promote pro-inflammatory, pro-coagulant, and pro-oxidative processes in diseases such as atherosclerosis, hypertension, and diabetes, yet they may also support endothelial survival and angiogenesis under certain physiological conditions [1, 18]. Elevated levels of circulating EMPs are widely recognized as sensitive biomarkers for endothelial dysfunction and vascular damage across a spectrum of cardiovascular and metabolic disorders [2, 5, 15]. Pharmacological interventions, such as statins, antiplatelet agents, and antihypertensive drugs, have been shown to modulate EMP production and levels, highlighting their potential as both diagnostic indicators and therapeutic targets for mitigating vascular complications [2, 11, 15, 19]. This modulation helps restore the balance between pro-thrombotic and anti-thrombotic factors, making EMPs a focal point for developing novel cardiovascular therapies [10, 18].

Other names

Endothelial microvesicleEndothelial-derived microparticleEndothelial-derived extracellular vesicleEMV

Reduction of endothelial activation and apoptosis to decrease microparticle shedding; improvement of endothelial nitric oxide synthase (eNOS) activity and reduction of oxidative stress.